All In Biotech

Drug Trial Radar · NCT05193409

A Phase 2 Study of BNC210 for the Acute Treatment of Social Anxiety Disorder

A Phase 2, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of BNC210 Compared to Placebo for the Acute Treatment of Social Anxiety Disorder

Last checked: Nov 19, 2026Latest source record: Mar 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 151 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

151

Actual

Start

Feb 2, 2022

Primary completion

Oct 10, 2022

Study completion Oct 17, 2022

Sponsor

Lead sponsor
Bionomics LimitedIndustry
Sponsor type
Industry
First posted
Jan 14, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the effects of an acute dose of BNC210 compared to placebo on reducing anxiety provoked by a speaking challenge and measured using the Subjective Units of Distress Scale (SUDS) in patients with Social Anxiety Disorder (SAD).

Conditions

  • Social Anxiety Disorder

Interventions

  • 225 mg BNC210Drug

    225 mg BNC210

  • 675 mg BNC210Drug

    675 mg BNC210

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline to the Average Subjective Units of Distress Scale (SUDS) Score of the 5-minute Performance Phase of a Public Speaking ChallengeTime frame: Assessed over a single visit: Baseline; and the Performance Phase (0,1,2,3,4,5 minutes) of the Public Speaking Challenge, conducted 1 hour post-dose.

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • PREVAIL Study Clinical Trial Site

    Beverly Hills, California

  • PREVAIL Study Clinical Trial Site

    Encino, California

  • PREVAIL Study Clinical Trial Site

    Glendale, California

  • PREVAIL Study Clinical Trial Site

    New Haven, Connecticut

  • PREVAIL Study Clinical Trial Site

    Lauderhill, Florida

  • PREVAIL Study Clinical Trial Site

    Miami, Florida

  • PREVAIL Study Clinical Trial Site

    Miami Lakes, Florida

  • PREVAIL Study Clinical Trial Site

    Decatur, Georgia

  • PREVAIL Study Clinical Trial Site

    Prairie Village, Kansas

  • PREVAIL Study Clinical Trial Site

    Boston, Massachusetts

  • PREVAIL Study Clinical Trial Site

    Princeton, New Jersey

  • PREVAIL Study Clinical Trial Site

    Brooklyn, New York

  • PREVAIL Study Clinical Trial Site

    Charlotte, North Carolina

  • PREVAIL Study Clinical Trial Site

    Cincinnati, Ohio

  • PREVAIL Study Clinical Trial Site

    Draper, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.